Change in pharmacokinetics of mycophenolic acid as a function of age in rats and effect of coadministered amoxicillin/clavulanate

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 7, 2012, Pages 1009-1013

  Ishizaki, Junko ^a   Tsuda, Tomoko ^a   Suga, Yukio ^a   Ito, Satsuki ^b   Arai, Kunizo ^a   Sai, Yoshimichi ^a,b   Miyamoto, Ken Ichi ^a,b  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Amoxicillin; Clavulanate; Enterohepatic circulation; Mycophenolic acid; Pharmacokinetics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MYCOPHENOLIC ACID;

AGING; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; ENTEROHEPATIC CIRCULATION; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT;

AGE FACTORS; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANIMALS; ANTI-BACTERIAL AGENTS; BILE; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; RATS; RATS, WISTAR;

EID: 84863555871     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b110639     Document Type: Article

References (24)

1. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm. Res., 7, 161-166 (1990).
2. Filler G. Optimization of immunosuppressive drug monitoring in children. Transplant. Proc., 39, 1241-1243 (2007).
3. Jacobson P, Huang J, Rydholm N, Tran M, Defor T, Tolar J, Orchard PJ. Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). J. Clin. Pharmacol., 48, 485-494 (2008).
4. Seebacher G, Weigel G, Wolner E, Mallinger R, Grimm M, Laufer G, El Menyawi I, Griesmacher A, Müller MM. A simple HPLC method for monitoring mycophenolic acid and its glucuronidated metabolite in transplant recipients. Clin. Chem. Lab. Med., 37, 409-415 (1999).
5. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm., 6, 547-558 (1978).
6. Kawai M, Bandiera SM, Chang TK, Bellward GD. Growth hormone regulation and developmental expression of rat hepatic CYP3A18, CYP3A9, and CYP3A2. Biochem. Pharmacol., 59, 1277-1287 (2000).
7. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, Ritter JK. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab. Dispos., 33, 1513-1520 (2005).
8. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet., 46, 13-58 (2007).
9. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut, 50, 259-265 (2002).
10. Lucier GW. Perinatal development of conjugative enzyme systems. Environ. Health Perspect., 18, 25-34 (1976).
11. Henderson PT. Metabolism of drugs in rat liver during the perinatal period. Biochem. Pharmacol., 20, 1225-1232 (1971).
12. Bustamante N, Cantarino MH, Arahuetes RM, Cubero FJ, Ortiz A. Evolution of the activity of UGT1A1 throughout the development and adult life in a rat. Life Sci., 78, 1688-1695 (2006).
13. Lindahl A, Krondahl E, Grudén AC, Ungell AL, Lennernäs H. Is the jejunal permeability in rats age-dependent? Pharm. Res., 14, 1278-1281 (1997).
14. Miyagi SJ, Collier AC. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab. Dispos., 35, 1587-1592 (2007).
15. Tamura S, Matsumoto Y. Comparative studies on postnatal development of liver β-glucuronidase activity between Gunn rats and Wistar rats. J. Toxicol. Sci., 5, 331-338 (1980).
16. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J. Pharmacol. Exp. Ther., 309, 1029-1035 (2004).
17. Takekuma Y, Kakiuchi H, Yamazaki K, Miyauchi S, Kikukawa T, Kamo N, Ganapathy V, Sugawara M. Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. J. Pharm. Pharm. Sci., 10, 71-85 (2007).
18. Khemawoot P, Maruyama C, Tsukada H, Noda H, Ishizaki J, Yokogawa K, Miyamoto K. Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride. Biopharm. Drug Dispos., 28, 331-338 (2007).
19. Zinchuk VS, Okada T, Akimaru K, Seguchi H. Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. Am. J. Physiol. Gastrointest. Liver Physiol., 282, G540-G548 (2002).
20. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann. Pharmacother., 37, 367-370 (2003).
21. Borrows R, Chusney G, Loucaidou M, James A, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D. The magnitude and time course of changes in mycophenolic acid 12-h predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation. Ther. Drug Monit., 29, 122-126 (2007).
22. Ohtsuki T, Mitsugi K, Ushizawa K, Esumi Y, Nanbo T, Yokoshima T, Koshima Y, Nishioka Y, Kumakura H, Langley PF. Pharmacokinetic studies on BRL25000. III. Study on the absorption, distribution and excretion of BRL14151 and AMPC following administration of BRL25000 to rats and dogs. Chemotherapy, 31 (Suppl. 2), 321-329 (1983).
23. Nakagawa K, Watanabe K, Hattori N, Yokota E. Phase I study on BRL25000 (clavulanic acid-amoxicillin). Chemotherapy, 30 (Suppl. 2), 98-110 (1982).
24. Toyonaga Y, Kurosu Y, Sugita M, Nakamura H, Takahashi T, Hori M. Fundamental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field. Jpn. J. Antibiot., 38, 373-413 (1985).